Next-Generation Weight-Loss Drugs Inhibit Brain Reward Circuits in Mice
A new study published in Nature reveals how next-generation small-molecule GLP-1 receptor agonists, such as orforglipron and danuglipron, modulate feeding behavior by inhibiting brain reward circuits. Researchers developed humanized GLP-1 receptor mouse models to overcome species-specific binding limitations that previously hindered mechanistic studies of these oral drugs. The investigation identified a specific neural pathway where these drugs engage Glp1r-expressing neurons in the central amygdala. This engagement suppresses the consumption of palatable foods by reducing dopamine release in the nucleus accumbens, effectively curbing hedonic feeding without affecting homeostatic energy balance mechanisms alone. The findings demonstrate that these weight-loss treatments regulate both metabolic and reward-driven eating through parallel neural circuits. This discovery provides critical insights into the neurological effects of orally available obesity treatments and suggests potential applications for managing substance-use disorders and binge eating. The research highlights the importance of understanding central nervous system engagement as these scalable, oral medications become more widely accessible for weight management.
Wire timeline
Next-Generation Weight-Loss Drugs Inhibit Brain Reward Circuits in Mice
A new study published in Nature reveals how next-generation small-molecule GLP-1 receptor agonists, such as orforglipron and danuglipron, modulate feeding behavior by inhibiting brain reward circuits. Researchers developed humanized GLP-1 receptor mouse models to overcome species-specific binding limitations that previously hindered mechanistic studies of these oral drugs. The investigation identified a specific neural pathway where these drugs engage Glp1r-expressing neurons in the central amygdala. This engagement suppresses the consumption of palatable foods by reducing dopamine release in the nucleus accumbens, effectively curbing hedonic feeding without affecting homeostatic energy balance mechanisms alone. The findings demonstrate that these weight-loss treatments regulate both metabolic and reward-driven eating through parallel neural circuits. This discovery provides critical insights into the neurological effects of orally available obesity treatments and suggests potential applications for managing substance-use disorders and binge eating. The research highlights the importance of understanding central nervous system engagement as these scalable, oral medications become more widely accessible for weight management.
Nature